StreetInsider.com News Articles

Form 144 MoonLake Immunotherapeut Filed by: Reich Kristian

Wed, 15 Jul 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260715/26774738.html

Form 144 MoonLake Immunotherapeut Filed by: Reich Kristian

Wed, 15 Jul 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260715/26774738.html

MoonLake Immunotherapeutics raises $30M as underwriters exercise overallotment option

Wed, 15 Jul 2026 06:04:58 -0400

MoonLake Immunotherapeutics (NASDAQ: MLTX) received $30.0 million in additional gross proceeds after underwriters exercised their overallotment option in full, according to a company statement.

The underwriters exercised their option on July 10, 2026, to purchase an additional 1,500,000 Class A ordinary shares at a par value of $0.0001 per share. The closing of the issuance and sale of those shares occurred on July 14, 2026.

The $30.0 million figure represents gross proceeds before deducting underwriting discounts, commissions, and offering expenses. The share sale was part of a previously announced public offering that also allowed certain investors to receive pre-funded warrants to purchase

MoonLake Immunotherapeutics raises $30M as underwriters exercise overallotment option

Wed, 15 Jul 2026 06:04:58 -0400

MoonLake Immunotherapeutics (NASDAQ: MLTX) received $30.0 million in additional gross proceeds after underwriters exercised their overallotment option in full, according to a company statement.

Form 8-K MoonLake Immunotherapeut For: Jul 14

Wed, 15 Jul 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260715/26770067.html

Form 8-K MoonLake Immunotherapeut For: Jul 14

Wed, 15 Jul 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260715/26770067.html

Form 4 MoonLake Immunotherapeut For: Jul 09 Filed by: Santos da Silva Jorge

Mon, 13 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260713/26762559.html

Form 4 MoonLake Immunotherapeut For: Jul 09 Filed by: Santos da Silva Jorge

Mon, 13 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260713/26762559.html

MoonLake Immunotherapeutics (MLTX) call put ratio 4.9 calls to 1 put with a focus on July and August 25 calls

Mon, 13 Jul 2026 14:31:29 -0400

MoonLake Immunotherapeutics (NASDAQ: MLTX) 30-day option implied volatility is at 120; compared to its 52-week range of 48 to 243. Call put ratio 4.9 calls to 1 put with a focus on July and August 25 calls.

Form 4 MoonLake Immunotherapeut For: Jul 01 Filed by: Santos da Silva Jorge

Thu, 02 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260702/26727795.html

Form 4 MoonLake Immunotherapeut For: Jul 01 Filed by: Santos da Silva Jorge

Thu, 02 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260702/26727795.html

Moonlake Immunotherapeutics (MLTX) PT Raised to $29 at Leerink

Wed, 01 Jul 2026 04:30:36 -0400

Leerink analyst Thomas J. Smith raised the price target on Moonlake Immunotherapeutics (NASDAQ: MLTX) to $29.00 (from $24.00) while maintaining a Outperform rating.

The analyst comments "We are increasingly confident in the potential for MLTX's (OP) sonelokimab (SLK, anti-IL-17A/F nanobody) in hidradenitis suppurativa (HS), following new data from the Phase 3 VELA program presented during the company's recent Investor Day event. Importantly, full 52-week data from VELA show compelling efficacy with long-term SLK treatment coupled with consistently clean safety/ tolerability—all of which support the drug's competitive profile in HS. MLTX remains on track for BLA submission towards the end of September,

Moonlake Immunotherapeutics (MLTX) PT Raised to $29 at Leerink

Wed, 01 Jul 2026 04:30:36 -0400

Leerink analyst Thomas J. Smith raised the price target on Moonlake Immunotherapeutics (NASDAQ: MLTX) to $29.00 (from $24.00) while maintaining a Outperform rating.

Form 144 MoonLake Immunotherapeut Filed by: Santos da Silva Jorge

Tue, 30 Jun 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260630/26714811.html

Form 144 MoonLake Immunotherapeut Filed by: Santos da Silva Jorge

Tue, 30 Jun 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260630/26714811.html

Form SCHEDULE 13D/A MoonLake Immunotherapeut Filed by: BIOTECHNOLOGY VALUE FUND L P

Mon, 29 Jun 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260629/26707652.html

Form SCHEDULE 13D/A MoonLake Immunotherapeut Filed by: BIOTECHNOLOGY VALUE FUND L P

Mon, 29 Jun 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260629/26707652.html

Form 8-K MoonLake Immunotherapeut For: Jun 23

Thu, 25 Jun 2026 06:19:00 -0400

si-local-file:///var/storage/secattach/20260625/26687715.html

Form 8-K MoonLake Immunotherapeut For: Jun 23

Thu, 25 Jun 2026 06:19:00 -0400

si-local-file:///var/storage/secattach/20260625/26687715.html

Form 424B5 MoonLake Immunotherapeut

Wed, 24 Jun 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260624/26686511.html

Form 424B5 MoonLake Immunotherapeut

Wed, 24 Jun 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260624/26686511.html

MoonLake prices $200 million public offering at $20 per share

Tue, 23 Jun 2026 23:08:40 -0400

MoonLake Immunotherapeutics (NASDAQ: MLTX) has priced an underwritten public offering of 9,000,000 Class A ordinary shares at $20.00 per share, according to a company statement. In addition, pre-funded warrants to purchase up to 1,000,000 Class A ordinary shares were offered at $19.9999 per warrant to certain investors in lieu of shares.

Gross proceeds from the offering are expected to be approximately $200 million before underwriting discounts, commissions, and other expenses. MoonLake has also granted underwriters a 30-day option to purchase up to an additional 1,500,000 Class A ordinary shares at the public offering price, less underwriting discounts and commissions.

The offering is

MoonLake prices $200 million public offering at $20 per share

Tue, 23 Jun 2026 23:08:40 -0400

The offering is

MoonLake prices $200 million public offering at $20 per share

Tue, 23 Jun 2026 23:08:40 -0400

The offering is

MoonLake prices $200 million public offering at $20 per share

Tue, 23 Jun 2026 23:08:40 -0400

The offering is